Company intelligence / Profile preview

New Biotic

United States

Ownership: Private
Development stage: Phase 1

Overview

RaphaLX™, their lead product for ALS, has shown promise in early tests, not only prolonging life but potentially reversing the condition in certain cases as demonstrated in limited human case studies. The company is preparing for Phase 2 trials.

Therapeutic areas: Neurology
Modalities: BiotherapeuticsProbiotics
Industry: Biotech

Drug pipeline

1 asset

RaphaLX

Unknown

Partnerships

Avera Institute for Human GeneticsAvera Health system

Beyond the preview

Go deeper on New Biotic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Biotic.

Explore the full profile